Introduction:: Due to the confounding heterogeneity, the therapeutic strategy for proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) remains to be defined. Case Representation:: We report a 38-year-old man with recurrent swelling of the eyelids and lower limbs, undergoing rituximab combined with steroid and tacrolimus treatment, who achieved an improved renal outcome. Underlying solid malignant tumours were excluded from the diagnosis. Discussion:: We treated patients with rituximab along with steroids and tacrolimus. Improvements in proteinuria and renal function were observed. We also reviewed the current literature to assess the efficacy of rituximab in the treatment of PGNMID. Conclusion:: However, a larger pool of patients and a longer follow-up period are required to establish the role of rituximab and steroids in the treatment of PGNMID.

中文翻译：

---

利妥昔单抗联合类固醇和他克莫司治疗伴单克隆 IgG 沉积的增殖性肾小球肾炎一例报告及文献复习

简介：由于混杂的异质性，伴有单克隆 IgG 沉积的增殖性肾小球肾炎 (PGNMID) 的治疗策略仍有待确定。病例描述：我们报告一名 38 岁男性，眼睑和下肢反复肿胀，接受利妥昔单抗联合类固醇和他克莫司治疗，肾脏预后得到改善。潜在的实体恶性肿瘤被排除在诊断之外。讨论：：我们使用利妥昔单抗以及类固醇和他克莫司治疗患者。观察到蛋白尿和肾功能的改善。我们还回顾了当前的文献来评估利妥昔单抗治疗 PGNMID 的疗效。结论：然而，需要更多的患者和更长的随访时间来确定利妥昔单抗和类固醇在 PGNMID 治疗中的作用。